Neuland Laboratories Ltd Net Profit is INR 17.29 crores in Quarter 4, January – March of Financial Year 2020-2021.
Quarterly Net Earnings Year-on-Year
Neuland Laboratories Ltd Quarter Net Profit is -286 % from Last Year Quarter Net Loss and Net Profit of INR 17.29 crores is reported in Quarter 4, January – March of Financial Year 2020-2021. Last Year Quarter 4, January – March of Financial Year 2019-2020 Net Loss was INR -9.3 crores.
Quarterly Net Sales Year-on-Year
Neuland Laboratories Ltd Quarter Sale is up 28 % from Last Quarter. Sales of 244.7 is reported in Quarter 4, January – March of Financial Year 2020-2021. In Last Year Quarter 4, January – March of Financial Year 2019-2020 Sale was 191.64
Annual Sales & Net Earning
Neuland Laboratories Ltd Annual Sales in Financial Year 2019 to 2020 was reported INR 762.71 crores and Annual Profit in Financial Year 2019 to 2020 was reported INR 16.21 crores.
Neuland Laboratories Ltd Stock Information
|Industry||Pharmaceuticals – Indian – Bulk Drugs|
|About||Neuland is primarily an API manufacturer with a large bouquet of products that find acceptance with over 500+ generics and innovator companies largely in regulated markets (Europe, North America and Japan). Apart from APIs, the company focused on the custom manufacturing services (CMS) segment. This R&D focused business vertical partners with global innovator companies for developing intermediates and APIs for their novel molecules. In addition, it also includes manufacturing APIs for commercial molecules in line with customer specifications.(|
|Latest Qaurter EPS||13.476327942903081|
Neuland Laboratories Ltd Stock Analysis: